Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality
Open Access
- 25 November 2020
- journal article
- research article
- Published by Elsevier BV in Atherosclerosis
- Vol. 317, 41-46
- https://doi.org/10.1016/j.atherosclerosis.2020.11.026
Abstract
No abstract availableKeywords
Funding Information
- Medical University of Vienna, Austria
This publication has 34 references indexed in Scilit:
- Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial diseaseAtherosclerosis, 2011
- Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expressionImmunobiology, 2011
- Full-length, Membrane-anchored TWEAK Can Function as a Juxtacrine Signaling Molecule and Activate the NF-κB PathwayOnline Journal of Public Health Informatics, 2010
- Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma RatioArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The CD163-expressing macrophages recognize and internalize TWEAK: Potential consequences in atherosclerosisAtherosclerosis, 2009
- The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targetingNature Reviews Drug Discovery, 2008
- Soluble CD163 from activated macrophages predicts mortality in acute liver failureJournal of Hepatology, 2007
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosisAtherosclerosis, 2006
- TWEAK Induces NF-κB2 p100 Processing and Long Lasting NF-κB ActivationOnline Journal of Public Health Informatics, 2003